Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

8.160 -0.190 (-2.28%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 957,074
Open 8.200
Bid (Size) 7.550 (100)
Ask (Size) 8.580 (400)
Prev. Close 8.350
Today's Range 7.930 - 8.240
52wk Range 2.315 - 15.74
Shares Outstanding 61,758,994
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics (NASDAQ:FULC) Q4 2025 Earnings: Pociredir Data Steals Spotlight Amid In-Line Financials ↗
Via Chartmill

Performance

YTD
-25.3%
-25.3%
1 Month
-22.2%
-22.2%
3 Month
-6.8%
-6.8%
6 Month
+18.6%
+18.6%
1 Year
+151.1%
+151.1%

More News

Read More
News headline image
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For October 29, 2025 ↗
Via Benzinga
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active
Via AB Newswire
News headline image
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Fulcrum Stock Nears March 2024 Highs: Early Stage Sickle-Cell Data Sparks Target Price Hikes ↗
Via Stocktwits
News headline image
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Gorilla Technology Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga
News headline image
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Fulcrum Therapeutics, Inc. - Common Stock publicly traded?
Yes, Fulcrum Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Fulcrum Therapeutics, Inc. - Common Stock trade on?
Fulcrum Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock?
The ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock is FULC on the Nasdaq Stock Market
What is the current price of Fulcrum Therapeutics, Inc. - Common Stock?
The current price of Fulcrum Therapeutics, Inc. - Common Stock is 8.160
When was Fulcrum Therapeutics, Inc. - Common Stock last traded?
The last trade of Fulcrum Therapeutics, Inc. - Common Stock was at 03/05/26 04:00 PM ET
What is the market capitalization of Fulcrum Therapeutics, Inc. - Common Stock?
The market capitalization of Fulcrum Therapeutics, Inc. - Common Stock is 503.95M
How many shares of Fulcrum Therapeutics, Inc. - Common Stock are outstanding?
Fulcrum Therapeutics, Inc. - Common Stock has 504M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.